<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04334707</url>
  </required_header>
  <id_info>
    <org_study_id>SITE00000750</org_study_id>
    <secondary_id>U2CDK114886</secondary_id>
    <secondary_id>UH3DK114861</secondary_id>
    <secondary_id>UH3DK114866</secondary_id>
    <secondary_id>UH3DK114870</secondary_id>
    <secondary_id>UH3DK114908</secondary_id>
    <secondary_id>UH3DK114915</secondary_id>
    <secondary_id>UH3DK114926</secondary_id>
    <secondary_id>UH3DK114907</secondary_id>
    <secondary_id>UH3DK114920</secondary_id>
    <secondary_id>UH3DK114923</secondary_id>
    <secondary_id>UH3DK114933</secondary_id>
    <secondary_id>UH3DK114937</secondary_id>
    <nct_id>NCT04334707</nct_id>
  </id_info>
  <brief_title>Kidney Precision Medicine Project</brief_title>
  <acronym>KPMP</acronym>
  <official_title>Kidney Precision Medicine Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Broad Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Molecular Biology Laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pacific Northwest National Laboratory</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Princeton University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute kidney injury (AKI) and chronic kidney disease (CKD) impose a significant global health
      burden. Yet, no effective therapies currently exist for AKI, and only a few are available for
      CKD.

      Despite significant effort from industry and academia, development of pharmacologic therapies
      for AKI and CKD has been hampered by:

      Non-predictive animal models The inability to identify and prioritize human targets The
      limited availability of human kidney biopsy tissue A poor understanding of AKI and CKD
      heterogeneity Historically, AKI and CKD have been described as single, uniform diseases.
      However, growing consensus suggests that different disease pathways lead to different
      subgroups of AKI and CKD (AKIs and CKDs).

      Access to human kidney biopsy tissue is a critical first step to define disease heterogeneity
      and determine the precise molecular pathways that will facilitate identification of specific
      drug targets and ultimately enable individualized care for people with AKI and CKD.

      A number of research centers across the United States are collaborating to bring
      state-of-the-art technologies together to:

        -  Ethically obtain and evaluate kidney biopsies from participants with AKI or CKD

        -  Define disease subgroups

        -  Create a kidney tissue atlas

        -  Identify critical cells, pathways, and targets for novel therapies

      The KPMP is made up of three distinct, but highly interactive, activity groups:

        -  Recruitment Sites: The recruitment sites (RS) are responsible for recruiting
           participants with AKI or CKD into the longitudinal study and performing the kidney
           biopsy.

        -  Tissue Interrogation Sites: The tissue interrogation sites (TIS) are responsible for
           developing and using innovative technologies to analyze the biopsy tissue.

        -  Central Hub: The central hub is responsible for aggregating, analyzing, and visualizing
           the generated data and providing scientific, infrastructure, and administrative support
           for the KPMP consortium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Kidney Precision Medicine Project (KPMP) is a prospective cohort study, whose goal is to
      use deep molecular phenotypes of kidney biopsies, along with longitudinally collected
      clinical phenotypic data, in order to develop new disease ontologies, classification systems,
      and treatments for acute kidney injury (AKI) and chronic kidney disease (CKD). Since its
      inception, the KPMP has sought out and included substantive patient-representative feedback
      regarding disease experience, lack of innovation in new kidney disease therapies and patient
      tolerance for risk levels in balance with potential benefits both to the individual and
      society.

      The KPMP Has publicly and operationally committed itself to always put participants and their
      best interests first and this foundational principle informs and undergirds every facet of
      the study. Both AKI and CKD are conditions that impose a significant global health burden.
      Yet, no effective therapies currently exist for AKI, and only a few are available for CKD.
      The network will utilize state-of-the-art methods to perform molecular interrogation of the
      tissue and to link the molecular data to kidney structure and clinical information in the
      form of a kidney tissue atlas.

      Molecular and imaging data derived from kidney tissue will be integrated with
      clinico-pathologic and genetic information, as well as other data derived from analyses of
      fluid biospecimens, including peripheral blood, urine, and stool. Using advanced analytics to
      integrate the data, KPMP will aim to define kidney disease subgroups in molecular terms by
      identifying critical cells, pathways and targets for novel therapies.

      Patients with AKI or CKD will be recruited from clinical care encounters (e.g., clinic visits
      for CKD patients, hospitalization or emergency room visits for AKI patients) and from
      electronic resources (e.g., existing registries, electronic health records). All study
      procedures are designed to optimize participant safety and will be ethically conducted,
      ensuring subjects fully understand the scope of the study and any possible risks.

      For each participant, kidney tissue will be obtained for molecular phenotyping and clinical
      diagnosis. The diagnostic interpretation will be returned to the participant's primary
      caregiver to inform clinical care, but no treatment interventions will be prescribed by the
      KPMP. In addition to kidney biopsy, the study will involve collection of baseline (time of
      biopsy) and longitudinal biospecimens (including urine, plasma, serum, DNA and stool) and
      demographic, clinical, and laboratory data. Participants will be followed through scheduled
      in-person and remote (telephone) study visits, as well as through periodic review of
      electronic health records.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biopsy-related outcomes</measure>
    <time_frame>Immediately after the procedure for up to 6 months</time_frame>
    <description>Biopsy-related complications will be collected by KPMP study staff using standardized case report forms. Clinical utility of the biopsy results will be assessed using standardized surveys of clinical providers, and participant-reported outcomes will be assessed using standardized questionnaires. Biopsy-related outcomes data will be collected around the time of the biopsy and within the six months following procurement of the kidney biopsy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kidney disease progression outcomes</measure>
    <time_frame>Through study completion (up to 10 years, depending on enrollment date of participant)</time_frame>
    <description>Longitudinal change in estimated glomerular filtration rate (eGFR):
Primary composite longitudinal outcome, defined by any of the following:
ESRD, defined as initiation of maintenance dialysis or kidney transplantation
Sustained decline in eGFR by 40% or more from baseline
Individual components of the primary composite outcome
Slope of eGFR change (from baseline to the latest value)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kidney disease progression outcomes</measure>
    <time_frame>Through study completion (up to 10 years, depending on enrollment date of participant)</time_frame>
    <description>Longitudinal change in urine albumin excretion defined by the following:
-Slope of change in urine albumin-creatinine ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kidney disease progression outcomes</measure>
    <time_frame>Through study completion (up to 10 years, depending on enrollment date of participant)</time_frame>
    <description>Longitudinal change in urine albumin excretion defined by the following:
-Change of Kidney Disease Improving Global Outcomes (KDIGO) albuminuria stage</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Participants with Additional Outcome Measures</measure>
    <time_frame>Through study completion (up to 10 years, depending on enrollment date of participant)</time_frame>
    <description>All-cause mortality, defined by death from any cause and validated through linkages with the National Death Index (NDI)
Cardiovascular events, including heart failure, myocardial infarction, cerebrovascular event, transient ischemic attack, thromboembolic event, arrhythmia, and cardiac arrest
New AKI events after KPMP enrollment
Hospital admissions and discharge diagnoses after KPMP enrollment</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants with Outcomes Specific to AKI</measure>
    <time_frame>Through study completion (up to 10 years, depending on enrollment date of participant)</time_frame>
    <description>Duration of AKI: number of days with elevated serum creatinine above baseline
Recovery of AKI: return of serum creatinine to greater than 125% of baseline by 3 months post-biopsy
ICU admissions: admissions to any intensive care unit during hospitalization
Need for dialysis: initiation and duration of any dialysis modality (CRRT, HD, or PD)
Length of hospital stay: number of days during initial AKE episode</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Acute Kidney Failure</condition>
  <condition>Acute Kidney Insufficiency</condition>
  <condition>Acute Renal Failure</condition>
  <condition>Acute Renal Injury</condition>
  <condition>Acute Renal Insufficiency</condition>
  <condition>Kidney Failure, Acute</condition>
  <condition>Kidney Insufficiency, Acute</condition>
  <condition>Renal Failure, Acute</condition>
  <condition>Renal Insufficiency, Acute</condition>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Chronic Kidney Insufficiency</condition>
  <condition>Chronic Renal Diseases</condition>
  <condition>Chronic Renal Insufficiency</condition>
  <condition>Kidney Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>Acute Kidney Injury Cohort</arm_group_label>
    <description>The focus will be on acute intrinsic non-glomerular disease, primarily on acute tubular necrosis (ATN). KPMP will also include a special population of patients at risk for AKI or with early AKI captured by an open (surgical) kidney biopsy performed at the time of clinically indicated laparotomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Kidney Diseases Cohort</arm_group_label>
    <description>High priority populations include CKD in the setting of diabetes (diabetic kidney disease, DKD) and hypertension-associated CKD (H-CKD). A special population of people with long-standing type 1 diabetes (more than 25 years) who remain free of clinically-evident DKD will also be included.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Kidney Biopsy</intervention_name>
    <description>A kidney biopsy is a procedure that involves taking a small piece of kidney tissue for examination with a microscope. A licensed health care provider will perform a kidney biopsy.</description>
    <arm_group_label>Acute Kidney Injury Cohort</arm_group_label>
    <arm_group_label>Chronic Kidney Diseases Cohort</arm_group_label>
    <other_name>Renal Biopsy</other_name>
    <other_name>Laparotomy</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Kidney (renal) tissue will be obtained from all study participants at study entry Blood and
      urine will be collected longitudinally, including DNA One-time stool sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The KPMP will focus on participant populations that account for large proportions of the
        public health burden of acute and chronic kidney diseases as evidenced by research and
        federal data.

        For CKD, high priority populations include CKD in the setting of diabetes (diabetic kidney
        disease, DKD) and hypertension-associated CKD (H-CKD). A special population of people with
        long-standing type 1 diabetes (more than 25 years) who remain free of clinically-evident
        DKD will also be included.

        For AKI, the focus will be on acute intrinsic non-glomerular disease, primarily on acute
        tubular necrosis (ATN). KPMP will also include a special population of patients at risk for
        AKI or with early AKI captured by an open (surgical) kidney biopsy performed at the time of
        clinically indicated laparotomy. The rationale for including this special AKI population is
        that AKI often occurs early in the clinical course of conditions like sepsis, major surgery
        and trauma.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Chronic Kidney Disease Subjects Inclusion Criteria Diabetic kidney disease (DKD)

          -  Diagnosis of diabetes mellitus (type 1 or 2) established by at least one of the
             following criteria:

               -  Hemoglobin A1C greater than or equal to 6.5%, confirmed with a repeat test within
                  the past year

               -  Fasting blood sugar greater than or equal to 126 mg/dL, confirmed with a repeat
                  test within the past year

               -  Use of glucose-lowering therapy (insulin or oral or other subcutaneous agents)

               -  International Classification of Diseases (ICD) 9/10 diagnostic code for diabetes

          -  Evidence of persistent kidney damage, manifest as any of the following present on at
             least two clinic assessments prior to enrollment and at least 3 months apart and
             excluding subjects with acute medical illnesses and changing kidney function:

               -  Estimated glomerular filtration rate 30-59 mL/min/1.73m2

               -  Estimated glomerular filtration rate greater than or equal to 60 mL/min/1.73m2
                  with urine albumin excretion greater than or equal to 30 mg/g creatinine (or
                  mg/day)

               -  Estimated glomerular filtration rate greater than or equal to 60 mL/min/1.73m2
                  with urine protein excretion greater than or equal to 150 mg/g creatinine (or
                  mg/day)

        Hypertension-associated Chronic Kidney Disease (H-CKD) Inclusion Criteria

          -  Diagnosis of hypertension (HTN) established by at least one of the following criteria:

               -  BP greater than 140/90 mmHg measured on three occasions over at least 1 month

               -  Taking antihypertensive medication for blood pressure (BP) control

               -  International Classification of Diseases (ICD) 9/10 diagnostic code for
                  hypertension

          -  Evidence of persistent kidney damage, manifested as any of the following present on at
             least two assessments at least 3 months apart and excluding subjects with acute
             medical illnesses and changing kidney function:

               -  Estimated glomerular filtration rate 30-59 mL/min/1.73m2 on two assessments at
                  least 3 months apart with albuminuria or proteinuria less than 2000 mg/g
                  creatinine (or mg/day)

               -  Estimated glomerular filtration rate greater than or equal to 60 mL/min/1.73m2
                  with urine albumin excretion 30-2000 mg/g creatinine (or mg/day)

               -  Estimated glomerular filtration rate greater than or equal to 60 mL/min/1.73m2
                  with urine protein excretion 150-2000 mg/g creatinine (or mg/day)

        Acute Kidney Injury Subjects Inclusion Criteria

        All three of the following criteria must be met:

          -  Baseline estimated glomerular filtration rate greater than 45 mL/min/1.73m2. Baseline
             defined by the median of the last three outpatient serum creatinine measurements from
             day 7 to 365 prior to enrollment.

               -  If only two measurements obtained within this window, the two results will be
                  averaged.

               -  If only one measurement was obtained within this window, this result will be used

               -  If baseline is missing the potential participant can be enrolled with an
                  estimated baseline, but only if there is no past medical history of chronic
                  kidney disease.

          -  Elevated serum creatinine (greater than or equal to 1.5 times baseline as defined
             above).

          -  And at least ONE of the following:

               -  A repeat serum creatinine within 48 hours of initial serum creatinine, showing a
                  further increase of 0.3 mg/dL

               -  Positive kidney injury urine biomarker, as defined by any of the following:

                    -  NGAL level greater than or equal to 150 ng/mL by ELISA or clinical analyzer

                    -  KIM1 level greater than or equal to 2.8 ng/mL by ELISA

                    -  TIMP2 x IGFBP7 greater than or equal to 2.0 by NephroCheckÂ®

               -  Urine microscopy suggestive of acute tubular necrosis defined as a urine
                  microscopy score of greater than or equal to 2.

                    -  greater than or equal to 1 Renal Tubular Epithelial cells (RTE) per high
                       powered field (HPF) AND greater than or equal to 1 granular cast/ low
                       powered field (LPF); or

                    -  greater than or equal to 5 Renal Tubular Epithelial cells (RTE) per high
                       powered field (HPF); or

                    -  greater than or equal to 5 granular cast/ low powered field (LPF)

        General Exclusion Criteria:

          -  Under 18 years of age

          -  Body Mass Index (BMI) greater than 40 kg/m2

          -  Allergy to iodinated contrast (any reaction)

          -  Pregnancy

          -  Malignancy - Receiving active chemotherapy or radiation to treat malignancy (except
             for nephrectomy tissue for reference and feasibility studies)

          -  Transplant recipient (includes solid transplant and bone marrow)

          -  Additional vulnerable individuals (incarcerated, institutionalized, or otherwise
             unable to participate in the study)

          -  Inability to provide informed consent

          -  Clinical diagnosis of kidney disease from an autoimmune disease, dysproteinemia, viral
             disease or glomerular disease other than DKD or H-CKD

          -  Unwilling to receive blood transfusion (if needed)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Himmelfarb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashveena Dighe, MS, MPH</last_name>
    <phone>206-744-4029</phone>
    <email>ashveena@nephrology.washington.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristina Blank, MPH</last_name>
    <phone>206-897-1957</phone>
    <email>blankk@uw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanima Arora, MD</last_name>
      <phone>203-640-6196</phone>
      <email>tanima.arora@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ugochukwu Ugwuowo, MD</last_name>
      <phone>203-809-2766</phone>
      <email>ugochukwu.ugwuowo@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Frances (Perry) Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dennis Moledina, MBBS, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Corona, MD</last_name>
      <phone>410-502-3852</phone>
      <email>pamelacorona@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rubab Malik</last_name>
      <phone>443-287-2771</phone>
      <email>rmalik9@jhu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Chirag Parikh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steve Menez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoe Kibbelaar</last_name>
      <phone>617-525-8445</phone>
      <email>zkibbelaar@bwh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mia Colona</last_name>
      <email>mia.colona@bmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sushrut Waikar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>48374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Slack</last_name>
      <phone>617-309-4130</phone>
      <email>Alison.Slack@joslin.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Neil Roy, MBBS</last_name>
      <phone>617-309-6165</phone>
      <email>Neil.Roy@joslin.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sylvia Rosas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stewart Lecker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Mehl, MD</last_name>
      <phone>212-851-5216</phone>
      <email>km3246@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Olivia Balderes</last_name>
      <phone>212-851-5216</phone>
      <email>ob2214@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Bomback, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Krzysztof Kiryluk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Barasch, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Cooperman, RN</last_name>
      <phone>216-444-7954</phone>
      <email>cooperl2@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Vivian Jeffers</last_name>
      <phone>216-444-4650</phone>
      <email>jefferv@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>John Sedor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilio Poggio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John O'Toole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Vita</last_name>
      <email>vitatm@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>James Winters</last_name>
      <email>wintersj4@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Palevsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Kellum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Rosengart, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas at Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Wang, RN</last_name>
      <phone>214-645-8267</phone>
      <email>Zhengnan.Wang@UTSouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Francisco Sanchez</last_name>
      <email>Francisco.Sanchez@utsouthwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Miguel Vazquez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Toto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>USGAO, Kidney disease research funding and priority setting. 2017: [online] https://www.gao.gov/assets/690/681714.pdf.</citation>
  </reference>
  <reference>
    <citation>RM, B., Social security amendments of 1972: summary and legislative history. 1973</citation>
  </reference>
  <reference>
    <citation>Rettig RA. Special treatment--the story of Medicare's ESRD entitlement. N Engl J Med. 2011 Feb 17;364(7):596-8. doi: 10.1056/NEJMp1014193. Erratum in: N Engl J Med. 2011 Apr 21;364(16):1582.</citation>
    <PMID>21323539</PMID>
  </reference>
  <reference>
    <citation>Norris KC, Williams SF, Rhee CM, Nicholas SB, Kovesdy CP, Kalantar-Zadeh K, Ebony Boulware L. Hemodialysis Disparities in African Americans: The Deeply Integrated Concept of Race in the Social Fabric of Our Society. Semin Dial. 2017 May;30(3):213-223. doi: 10.1111/sdi.12589. Epub 2017 Mar 9. Review.</citation>
    <PMID>28281281</PMID>
  </reference>
  <reference>
    <citation>Prevention, C.f.D.C.a., National Chronic Kidney Disease Fact Sheet, 2017, U.D.o.H.a.H. Services, Editor. 2017: Atlanta, GA.</citation>
  </reference>
  <reference>
    <citation>Mendu ML, Erickson KF, Hostetter TH, Winkelmayer WC, Olan G, Meyer RN, Hakim R, Sedor JR. Federal Funding for Kidney Disease Research: A Missed Opportunity. Am J Public Health. 2016 Mar;106(3):406-7. doi: 10.2105/AJPH.2015.303009.</citation>
    <PMID>26885959</PMID>
  </reference>
  <reference>
    <citation>Linde PG, Archdeacon P, Breyer MD, Ibrahim T, Inrig JK, Kewalramani R, Lee CC, Neuland CY, Roy-Chaudhury P, Sloand JA, Meyer R, Smith KA, Snook J, West M, Falk RJ. Overcoming Barriers in Kidney Health-Forging a Platform for Innovation. J Am Soc Nephrol. 2016 Jul;27(7):1902-10. doi: 10.1681/ASN.2015090976. Epub 2016 Apr 28.</citation>
    <PMID>27127187</PMID>
  </reference>
  <reference>
    <citation>Inrig JK, Califf RM, Tasneem A, Vegunta RK, Molina C, Stanifer JW, Chiswell K, Patel UD. The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov. Am J Kidney Dis. 2014 May;63(5):771-80. doi: 10.1053/j.ajkd.2013.10.043. Epub 2013 Dec 6. Review.</citation>
    <PMID>24315119</PMID>
  </reference>
  <reference>
    <citation>Hsu RK, McCulloch CE, Dudley RA, Lo LJ, Hsu CY. Temporal changes in incidence of dialysis-requiring AKI. J Am Soc Nephrol. 2013 Jan;24(1):37-42. doi: 10.1681/ASN.2012080800. Epub 2012 Dec 6.</citation>
    <PMID>23222124</PMID>
  </reference>
  <reference>
    <citation>Lameire NH, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, Liu KD, Mehta RL, Pannu N, Van Biesen W, Vanholder R. Acute kidney injury: an increasing global concern. Lancet. 2013 Jul 13;382(9887):170-9. doi: 10.1016/S0140-6736(13)60647-9. Epub 2013 May 31. Review.</citation>
    <PMID>23727171</PMID>
  </reference>
  <reference>
    <citation>Collister D, Pannu N, Ye F, James M, Hemmelgarn B, Chui B, Manns B, Klarenbach S; Alberta Kidney Disease Network. Health Care Costs Associated with AKI. Clin J Am Soc Nephrol. 2017 Nov 7;12(11):1733-1743. doi: 10.2215/CJN.00950117. Epub 2017 Oct 19.</citation>
    <PMID>29051143</PMID>
  </reference>
  <reference>
    <citation>Kellum JA, Bellomo R, Ronco C. Kidney attack. JAMA. 2012 Jun 6;307(21):2265-6. doi: 10.1001/jama.2012.4315.</citation>
    <PMID>22572776</PMID>
  </reference>
  <reference>
    <citation>USRDS, United States Renal Data Systems 2013 Annual Data Report. United States Renal Data Systems. 2013: [online] http://http://www.usrds.org/2013/pdf/v1_ch6_13.pdf.</citation>
  </reference>
  <reference>
    <citation>Waikar SS, Liu KD, Chertow GM. Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol. 2008 May;3(3):844-61. doi: 10.2215/CJN.05191107. Epub 2008 Mar 12. Review.</citation>
    <PMID>18337550</PMID>
  </reference>
  <reference>
    <citation>Sileanu FE, Murugan R, Lucko N, Clermont G, Kane-Gill SL, Handler SM, Kellum JA. AKI in low-risk versus high-risk patients in intensive care. Clin J Am Soc Nephrol. 2015 Feb 6;10(2):187-96. doi: 10.2215/CJN.03200314. Epub 2014 Nov 25.</citation>
    <PMID>25424992</PMID>
  </reference>
  <reference>
    <citation>Murugan R, Karajala-Subramanyam V, Lee M, Yende S, Kong L, Carter M, Angus DC, Kellum JA; Genetic and Inflammatory Markers of Sepsis (GenIMS) Investigators. Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival. Kidney Int. 2010 Mar;77(6):527-35. doi: 10.1038/ki.2009.502. Epub 2009 Dec 23.</citation>
    <PMID>20032961</PMID>
  </reference>
  <reference>
    <citation>Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009 Jun;53(6):961-73. doi: 10.1053/j.ajkd.2008.11.034. Epub 2009 Apr 5. Review.</citation>
    <PMID>19346042</PMID>
  </reference>
  <reference>
    <citation>Waikar SS, Winkelmayer WC. Chronic on acute renal failure: long-term implications of severe acute kidney injury. JAMA. 2009 Sep 16;302(11):1227-9. doi: 10.1001/jama.2009.1364.</citation>
    <PMID>19755705</PMID>
  </reference>
  <reference>
    <citation>Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012 Mar;81(5):442-8. doi: 10.1038/ki.2011.379. Epub 2011 Nov 23. Review.</citation>
    <PMID>22113526</PMID>
  </reference>
  <reference>
    <citation>Kellum JA, Sileanu FE, Murugan R, Lucko N, Shaw AD, Clermont G. Classifying AKI by Urine Output versus Serum Creatinine Level. J Am Soc Nephrol. 2015 Sep;26(9):2231-8. doi: 10.1681/ASN.2014070724. Epub 2015 Jan 7.</citation>
    <PMID>25568178</PMID>
  </reference>
  <reference>
    <citation>AKIWG, K., Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Acute Kidney Injury. Kidney inter., Suppl., 2012. 2: p. 1-138.</citation>
  </reference>
  <reference>
    <citation>Chu R, Li C, Wang S, Zou W, Liu G, Yang L. Assessment of KDIGO definitions in patients with histopathologic evidence of acute renal disease. Clin J Am Soc Nephrol. 2014 Jul;9(7):1175-82. doi: 10.2215/CJN.06150613. Epub 2014 May 1.</citation>
    <PMID>24789552</PMID>
  </reference>
  <reference>
    <citation>Perazella MA, Coca SG, Hall IE, Iyanam U, Koraishy M, Parikh CR. Urine microscopy is associated with severity and worsening of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol. 2010 Mar;5(3):402-8. doi: 10.2215/CJN.06960909. Epub 2010 Jan 14.</citation>
    <PMID>20089493</PMID>
  </reference>
  <reference>
    <citation>Corapi KM, Chen JL, Balk EM, Gordon CE. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis. 2012 Jul;60(1):62-73. doi: 10.1053/j.ajkd.2012.02.330. Epub 2012 Apr 24. Review.</citation>
    <PMID>22537423</PMID>
  </reference>
  <reference>
    <citation>Rodriguez LL, Brooks LD, Greenberg JH, Green ED. Research ethics. The complexities of genomic identifiability. Science. 2013 Jan 18;339(6117):275-6. doi: 10.1126/science.1234593.</citation>
    <PMID>23329035</PMID>
  </reference>
  <results_reference>
    <citation>CfMaM., S., Chronic Conditions among medicare beneficiaries. Chartbook, 2012 Edition. Baltimore 2012.</citation>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Jonathan Himmelfarb</investigator_full_name>
    <investigator_title>Professor, School of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

